Telomeres, located at the ends of chromosomes, consist of long TTAGGG nucleotide repeats and an associated protein complex. Chromosome ends are protected from end-to-end fusion and degradation by this telomere complex, termed shelterin ([de Lange, 2005](#bib10){ref-type="other"}). The TTAGGG repeats shorten with each cell division, and eventually reach a critical state, at which time cellular senescence and/or apoptosis is normally triggered ([Rodier *et al*, 2005](#bib22){ref-type="other"}). Tumour cells may survive cellular crisis in the absence of chromosomal stability through the activation or inactivation of alternative pathways. Breast cancer fits the paradigm of dysfunctional telomere-induced genomic instability, because the transition of breast duct hyperplasia to ductal carcinoma *in situ* likely results from a period of telomere crisis ([DePinho, 2000](#bib12){ref-type="other"}; [Chin *et al*, 2004](#bib5){ref-type="other"}). As breast cancer progresses further to invasive and metastatic stages, telomere dysfunction and genomic instability become more apparent ([Nishizaki *et al*, 1997](#bib19){ref-type="other"}; [Buerger *et al*, 1999](#bib4){ref-type="other"}; [Chin *et al*, 2004](#bib5){ref-type="other"}). As cells progress through the latter stages of carcinogenesis, telomeres become relatively stable. In addition, low-telomere DNA content was found to be an independent predictor of decreased survival in comparisons of breast cancer specimens to normal tissues ([Chin *et al*, 2004](#bib5){ref-type="other"}; [Fordyce *et al*, 2006](#bib13){ref-type="other"}).

Most genes involved in telomere biology are highly conserved between species and have limited nucleotide diversity in humans ([de Lange, 2004](#bib9){ref-type="other"}; [Savage *et al*, 2005](#bib23){ref-type="other"}). We hypothesized that common genetic variation (minor allele frequency (MAF) greater than 5%) in the form of single nucleotide polymorphisms (SNPs) in these genes could affect cancer risk. This hypothesis was investigated in a population-based case--control study of breast cancer study in Poland, in which we genotyped 24 common SNPs that captured most of the common genetic variation in five genes important in telomere biology. The studied genes included telomerase (TERT (protein name), *TERT* (*HUGO* gene name), 5p15.33) ([Collins and Mitchell, 2002](#bib7){ref-type="other"}), telomerase-associated protein (TP1, *TEP1*, 14q11.2) ([Poderycki *et al*, 2005](#bib21){ref-type="other"}), telomeric repeat-binding factor 1 (TRF1, *TERF1*, 8q13) ([Smogorzewska *et al*, 2000](#bib24){ref-type="other"}), telomeric repeat-binding factor 2 (TRF2, *TERF2*, 16q22.1) ([Chong *et al*, 1995](#bib6){ref-type="other"}; [Broccoli *et al*, 1997](#bib3){ref-type="other"}) and protection of telomeres 1 (POT1, *POT1*, 7q31.33) ([Baumann and Cech, 2001](#bib1){ref-type="other"}).

MATERIALS AND METHODS
=====================

Study population
----------------

The design of this population-based breast cancer case--control study has been described ([Garcia-Closas *et al*, 2006a](#bib14){ref-type="other"}). Eligible cases included women aged 20--74 years who were Polish residents of either Warsaw or Łódź with pathologically or cytologically confirmed *in situ* or invasive breast cancer, newly diagnosed in 2000--2003. An estimated 90% of eligible cases were identified through a rapid identification system at five participating hospitals. Information from Cancer Registries was used to identify the remaining 10% of eligible breast cancer cases. Eligible control subjects were residents of Warsaw and Łódź who did not have a history of breast cancer at enrollment. Controls were randomly selected from population lists, and frequency-matched to breast cancer cases by city and 5-year age groups. Women provided a personal interview on known and suspected risk factors. Venous blood samples were collected by a trained nurse. The study protocol was reviewed and approved by local and National Cancer Institute (NCI) Institutional Review Boards. All participants provided written informed consent. Of the 3037 eligible cases and 3639 eligible controls identified, 2386 (79%) cases and 2502 (69%) controls agreed to participate in the personal interview. The present study is limited to women with blood DNA samples: 1995 cases (6% *in situ*) and 2296 controls, which represented 84 and 94%, respectively, of the study population.

Laboratory methods
------------------

Genomic DNA for genotype analyses was isolated from buffy coat or whole blood samples using the Autopure LS® DNA Purification System (Gentra Systems Inc., Minneapolis, MN, USA). Twenty-four SNPs in *POT1*, *TEP1*, *TERF1*, *TERF2*, and *TERT* were genotyped by investigators blinded to case--control status, using TaqMan or MGB Eclipse platforms at the Core Genotyping Facility of the Division of Cancer Epidemiology and Genetics, NCI ([Table 1](#tbl1){ref-type="table"}). Assay conditions are available at <http://snp500cancer.nci.nih.gov> ([Packer *et al*, 2006](#bib20){ref-type="other"}). When possible, rs numbers based on the dbSNP database are indicated (<http://www.ncbi.nlm.nih.gov/SNP>). If an rs number has not yet been assigned, an E number (e.g. E3675_301) is provided, based on nomenclature from the SNP500Cancer project ([Packer *et al*, 2006](#bib20){ref-type="other"}). Single nucleotide polymorphism locations were determined using the guidelines of the Human Genome Variation Society ([den Dunnen and Antonarakis, 2001](#bib11){ref-type="other"}).

A total of 100 duplicate DNA pairs were ⩾98% concordant for each SNP with the exception of *TERF1* IVS9-163T\>C (rs3863242, 97%) and *TERT* Ex2-659G\>A (rs2736098, 94%). Genotypes were called for \>98% of all SNPs. Genotype frequencies for all loci were in Hardy--Weinberg equilibrium among controls.

Single nucleotide polymorphism selection
----------------------------------------

Initial SNP selection criteria included MAF greater than 5% in Caucasians from SNP500 Cancer (*n*=31), even spacing across the gene, SNPs with potential functional implications and/or patterns of nucleotide diversity and linkage disequilibrium (LD) previously determined through extensive re-sequence analysis ([Savage *et al*, 2005](#bib23){ref-type="other"}; [Packer *et al*, 2006](#bib20){ref-type="other"}) and assay availability at the time of SNP selection. The SNPs selected using these criteria were evaluated as haplotype-tagging SNPs compared with all common SNPs identified in the prior re-sequence analysis using tagSNPs ([Stram, 2004](#bib27){ref-type="other"}) and TagZilla (<http://tagzilla.nci.nih.gov/>). *R*^2^~H~ was the pairwise correlation coefficient between SNPs determined by these programs. SNPs with *R*^2^~H~ ⩾0.8 were considered highly correlated.

*TEP1* (54 exons, 40.7 kilobase pairs (kbp)) has minimal LD and eight common SNPs in the 31 SNP500 Caucasians. The five *TEP1* SNPs genotyped ([Table 1](#tbl1){ref-type="table"}) gave an *R*^2^~H~ of 0.84, indicating representative coverage of common genetic variation across *TEP1*. *TERF1* (10 exons, 15.3 kbp) has very limited nucleotide diversity with only four common SNPs in SNP500 Caucasians between introns 7 and 9 ([Savage *et al*, 2005](#bib23){ref-type="other"}). Three of these SNPs were genotyped and very good correlation for the fourth SNP was noted, *R*^2^~H~=1.0. *TERF2* (10 exons, 30.3 kbp) has only four common SNPs between introns 1 and 8 and a very small common haplotype block between introns 6 and 7 ([Savage *et al*, 2005](#bib23){ref-type="other"}). *TERF2* IVS6+27G\>A and IVS7-42T\>C were highly correlated with the other SNP in this block, *TERF2* IVS8+95T\>C (E3675_301) (*R*^2^~H~\>0.8), but did not cover the SNP in intron 1 (*TERF1* IVS1-5C\>T, E5055_301), which only had a MAF of 5% in SNP500 Caucasians. Studies of genetic variation in *TERT* (41.9 kbp, 16 exons) are complex due to low nucleotide diversity and limited LD ([Savage *et al*, 2005](#bib23){ref-type="other"}). The 10 SNPs genotyped in our study spanned 43 kbp from −1654A\>G to Ex16+203C\>T and were representative of common genetic variation, *R*^2^~H~=0.63. We were unable to genotype *TERT* Ex14+7C\>T (E3661_301, H1001H) due to lack of assay availability, which would have increased the *R*^2^~H~ to 0.83; however, we did genotype Ex16+203C\>T (rs2853690), which was only 1776 bp 3′ of *TERT* Ex14+7C\>T. The four SNPs genotyped in *POT1* (17 exons, 74.7 kbp) spanned 73.1 kbp (−1386G\>A through IVS13-98T\>G), a region with strong LD and 11 common SNPs in SNP500 Caucasians ([Savage *et al*, 2005](#bib23){ref-type="other"}). These SNPs ([Table 1](#tbl1){ref-type="table"}) were good representatives of common genetic variation across *POT1*, *R*^2^~H~=1.0.

Statistical analyses
--------------------

Odds ratios (OR) and 95% confidence intervals (CI) from logistic regression models with dummy variables for matching factors (age in 5-year categories and study site (Warsaw or Łódź)) were used to estimate relative risks for the genotypes examined. The association between genotypes and breast cancer risk was tested using a 2 degrees of freedom (df) likelihood ratio test and a trend test. Heterogeneity of genotype ORs among groups of women defined by age categories and family history of breast cancer in first-degree relatives were evaluated by introducing interaction terms in logistic regression models. A positive family history was defined for women reporting one or more first-degree relatives diagnosed with breast cancer in the study questionnaire. An additive genetic model was assumed in interaction analyses. Age was considered as a continuous variable in tests for genotype--age interactions. Haplotypes were constructed for cases and controls using PHASE v2.1 ([Stephens *et al*, 2001](#bib26){ref-type="other"}; [Stephens and Donnelly, 2003](#bib25){ref-type="other"}) and HaploStats ([Lake *et al*, 2003](#bib17){ref-type="other"}). The global case--control permutation test was performed using PHASE v2.1 ([Stephens *et al*, 2001](#bib26){ref-type="other"}; [Stephens and Donnelly, 2003](#bib25){ref-type="other"}). HaploStats ([Lake *et al*, 2003](#bib17){ref-type="other"}) was used also to determine the global score *P*-value, haplotype frequencies, ORs and 95% CIs.

RESULTS
=======

Most cases (74%) and controls (69%) in the study were postmenopausal, and cases were diagnosed at an average age (standard deviation) of 56 (±10) years. The established risk factors were associated with breast cancer risk in comparable direction with similar estimates of magnitude reported by others ([Garcia-Closas *et al*, 2006b](#bib15){ref-type="other"}).

Case--control analyses showed no statistically significant associations between the 24 SNPs in *TEP1*, *TERF1*, *TERF2*, *TERT* and *POT1* and risk of breast cancer ([Table 1](#tbl1){ref-type="table"}). Specific haplotypes derived from the evaluated SNPs were also not associated with increased risk of breast cancer in this study (data not shown). There were no statistically significant associations among age, SNP and breast cancer risk ([Supplementary Table 1](#sup1){ref-type="other"}).

Case--control analyses suggested inverse associations between homozygous variants of *TERT* and breast cancer risk at two SNP sites, *TERT*-1654A\>G (OR 0.85, 95% CI 0.72--1.02) and *TERT* Ex2-659G\>A (A305A) (OR 0.76, 95% CI 0.58--1.00) ([Table 1](#tbl1){ref-type="table"}). The inverse association of *TERT* Ex2-659G\>A (A305A) and two other linked *TERT* SNPs appeared to be limited to individuals with a family history of breast cancer in first-degree female relatives, −1381C\>T (OR 0.73, 95% CI 0.53--1.00), −244C\>T (OR 0.66, 95% CI 0.46--0.95), and Ex2-659G\>A (A305A) (OR 0.57, 95% CI 0.39--0.84) ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="other"}). These SNPs were not significantly related to family history of cancer among the control population, and analyses of breast cancer cases with a family history of breast cancer compared with all controls, regardless of family history, produced similar results (data not shown). These three SNPs appeared to be in LD by D′, but only −244C\>T and Ex2-659G\>A were strongly correlated with *R*^2^~H~ of 0.79. *TERT*-1381C\>T, −244C\>T, and Ex2-659G\>A had high pairwise D′ values, but the *R*^2^~H~ showed that only −244C\>T and Ex2-659G\>A were highly correlated. This suggests that the associations seen in *TERT* −1381C\>T may not be related to the effects of LD between this SNP, −244C\>T and Ex2-659G\>A. However, the statistical association seen in −244C\>T and Ex2-659G\>A could be because they are highly correlated, and in effect, measure the same risk marker.

Haplotype analyses were performed for all SNPs studied in *TERT* and for each of the two major haplotype blocks in *TERT* (block 1: −1654A\>G, −1381C\>T, −967T\>C, −244C\>T and Ex2-659G\>A, block 2: IVS10+269C\>T and Ex16+203C\>T). There were no significant associations for haplotypes in the primary case--control analysis (data not shown). However, a block 1 haplotype (ATCCA) in *TERT* was associated with protection from breast cancer when only individuals with a family history of breast cancer were studied (OR 0.61, 95% CI 0.38--0.97, *P*=0.034).

In addition, women with a family history also showed a borderline statistically significant positive association between *TERF2* IVS-42T\>C variant alleles and breast cancer risk (OR 1.57, 96% CI 0.97--2.55, *P* interaction 0.06). No other associations were significantly modified by family history of breast cancer ([Supplementary Table 2](#sup1){ref-type="other"}).

DISCUSSION
==========

To our knowledge, this is the first study to investigate genetic variation within genes important in telomere biology (*POT1*, *TEP1*, *TERF1*, *TERF2* and *TERT*) and breast cancer risk. The SNPs genotyped were representative of common genetic variation across the genomic region of interest, and showed no significant overall associations with breast cancer risk. However, data suggested association between variants in *TERT* among women with a positive family history of breast cancer.

*TERT* Ex2-659G\>A showed a borderline statistically significant association with a reduced risk of breast cancer in analysis of all cases and controls, which appeared to be stronger for individuals with a family history of breast cancer. Similar associations of two other SNPs, −1381C\>T and −244C\>T, in individuals with a family history of breast cancer were also noted. *TERT* −244T\>C was noted to have increased telomerase activity related to the T allele in a recent study of non-small cell lung cancer ([Hsu *et al*, 2006](#bib16){ref-type="other"}). *TERT* −1381C\>T also appears to be a functional SNP. Studies of promoter function at this site (noted at −1327 by the authors, but with the same rs number, rs2735940) suggested longer telomere length in with TT homozygotes compared with CC ([Matsubara *et al*, 2006](#bib18){ref-type="other"}). Our findings suggested that variants in *TERT* could have an effect in individuals already at increased genetic risk of breast cancer, although the number of individuals with a family history of breast cancer was small.

*TERF2* IVS6+27G\>A (E3673_301) was also associated with a reduced risk of breast cancer in individuals with a family history of breast cancer, however, the functional significance of the SNP is unknown. It does not appear to affect an intron--exon splice site ([Conde *et al*, 2004](#bib8){ref-type="other"}).

The SNPs evaluated in this study were chosen based on previous knowledge of common genetic variation resulting from re-sequence analysis, captured most of the common variation in the five studied genes (i.e. *POT1*, *TEP1*, *TERF1*, *TERF2* and *TERT)*, and could be related to breast cancer risk based on the role suggested for telomere biology in this disease ([Baykal *et al*, 2004](#bib2){ref-type="other"}; [Wacholder *et al*, 2004](#bib28){ref-type="other"}; [Savage *et al*, 2005](#bib23){ref-type="other"}). Although associations with less common SNPs are possible, our data indicate that common variation in these genes is unlikely to substantially affect overall breast cancer risk. The associations of *TERT* −1381C\>T, −244C\>T, Ex2-659G\>A and the corresponding haplotype in individuals with a family history of breast cancer are intriguing and warrant follow-up in independent studies.

External data objects {#sup1}
=====================

###### Supplementary Tables 1 and 2
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###### 

Association between 24 single nucleotide polymorphisms in five genes important in telomere biology and breast cancer risk among cases and controls

                                 **Controls**   **Cases**                                           
  --------- --------------- ---- -------------- ----------- ------ ---- ------ ------ ------ ------ ------
  *TEP1*    Ex1-222 T\>C     TT  1089           48          959    49   1.00                         
            S116P            TC  972            43          831    42   0.97   0.86   1.11   0.68    
            Rs1760897        CC  203            9           183    9    1.02   0.82   1.27   0.84   0.93
            Ex4+51 C\>A      CC  1514           67          1318   67   1.00                         
            N307K            CA  657            29          572    29   1.00   0.87   1.14   0.96    
            rs1760898        AA  89             4           75     4    0.96   0.70   1.32   0.80   0.85
            IVS13+84T\>C     TT  795            35          712    36   1.00                         
            rs872072         TC  1078           47          928    47   0.97   0.84   1.10   0.61    
                             CC  413            18          337    17   0.91   0.77   1.09   0.32   0.32
            Ex24+49 T\>C     TT  625            28          503    26   1.00                         
            S1195P           TC  1096           48          967    49   1.10   0.95   1.27   0.22    
            rs1760904        CC  540            24          495    25   1.14   0.97   1.35   0.12   0.12
            Ex45+36 G\>A     GG  1433           63          1279   64   1.00                         
            V2214I           GA  760            33          616    31   0.91   0.79   1.03   0.14    
            rs1713449        AA  88             4           92     5    1.18   0.87   1.60   0.28   0.66
                                                                                                     
  *TERF1*   IVS7+82C\>T      CC  1360           60          1146   58   1.00                         
            E3663_301        CT  812            36          731    37   1.07   0.94   1.21   0.31    
                             TT  106            5           106    5    1.19   0.89   1.57   0.24   0.15
            IVS8-124G\>A     GG  983            44          836    43   1.00                         
            rs2306494        GA  1017           45          885    45   1.02   0.90   1.17   0.72    
                             AA  254            11          225    12   1.05   0.86   1.28   0.65   0.61
            IVS9-163T\>C     TT  754            32          740    34   1.00                         
            rs3863242        TC  1152           49          1060   48   0.93   0.82   1.06   0.30    
                             CC  437            19          401    18   0.93   0.79   1.11   0.43   0.35
                                                                                                     
  *TERF2*   IVS6+27G\>A      GG  1603           70          1389   70   1.00                         
            E3673_301        GA  612            27          535    27   1.01   0.88   1.16   0.88    
                             AA  63             3           50     3    0.92   0.63   1.34   0.66   0.90
            IVS7-42T\>C      TT  1081           47          894    45   1.00                         
            rs251796         TC  960            42          873    44   1.10   0.97   1.25   0.13    
                             CC  242            11          218    11   1.09   0.89   1.34   0.39   0.17
                                                                                                     
  *TERT*    −1654A\>G        AA  702            31          664    33   1.00                         
            rs2736109        AG  1132           50          963    49   0.90   0.78   1.03   0.13    
                             GG  443            19          357    18   0.85   0.72   1.02   0.08   0.06
            −1381C\>T        CC  695            29          634    29   1.00                         
            rs2735940        CT  1167           49          1121   51   1.05   0.92   1.20   0.46    
                             TT  498            21          447    20   0.98   0.83   1.15   0.78   0.87
            −967T\>C         TT  1671           73          1409   72   1.00                         
            rs7712562        TC  556            24          510    26   1.09   0.94   1.25   0.24    
                             CC  47             2           47     2    1.17   0.77   1.76   0.46   0.18
            −244C\>T         CC  1224           54          1095   55   1.00                         
            rs2853669        CT  900            39          766    39   0.95   0.84   1.08   0.42    
                             TT  158            7           124    6    0.87   0.68   1.11   0.27   0.22
            Ex2-659G\>A      GG  1313           58          1171   60   1.00                         
            A305A            GA  811            36          699    36   0.97   0.85   1.10   0.59    
            rs2736098        AA  141            6           97     5    0.76   0.58   1.00   0.05   0.11
            IVS2-4601C\>T    CC  1082           47          915    46   1.00                         
            rs2736099        CT  957            42          857    43   1.05   0.93   1.20   0.42    
                             TT  241            11          212    11   1.04   0.84   1.27   0.73   0.51
            IVS2-4455C\>T    CC  890            39          738    37   1.00                         
            rs2853677        CT  1062           47          950    48   1.08   0.94   1.23   0.27    
                             TT  330            14          294    15   1.07   0.89   1.29   0.48   0.34
            IVS3-24T\>C      TT  1731           76          1495   75   1.00                         
            rs13167280       TC  518            23          460    23   1.03   0.89   1.19   0.71    
                             CC  36             2           31     2    0.99   0.61   1.61   0.97   0.77
            IVS10+269C\>T    CC  936            41          818    41   1.00                         
            rs2075786        CT  1062           47          918    46   0.99   0.87   1.13   0.93    
                             TT  283            12          244    12   0.99   0.82   1.21   0.95   0.93
            Ex16+203C\>T     CC  1660           73          1454   74   1.00                         
            rs2853690        CT  561            25          467    24   0.95   0.82   1.09   0.45    
                             TT  49             2           43     2    1.00   0.66   1.52   0.99   0.55
                                                                                                     
  *POT1*    −1386G\>A        GG  966            42          851    43   1.00                         
            E5047_301        GA  1055           46          913    46   0.98   0.86   1.11   0.74    
                             AA  256            11          221    11   0.98   0.80   1.20   0.84   0.76
            IVS6-33G\>A      GG  968            43          847    43   1.00                         
            rs7784168        GA  1052           46          906    46   0.98   0.86   1.12   0.77    
                             AA  249            11          220    11   1.01   0.82   1.24   0.94   0.94
            IVS12-111G\>A    GG  1260           53          1154   52   1.00                         
            rs10263573       GA  914            39          897    41   1.07   0.95   1.21   0.25    
                             AA  185            8           155    7    0.91   0.73   1.15   0.44   0.86
            IVS13-98T\>G     TT  909            39          861    39   1.00                         
            rs10250202       TG  1111           47          1026   47   0.97   0.86   1.10   0.65    
                             GG  332            14          314    14   1.00   0.84   1.20   0.98   0.88

Abbreviations: N=number of individuals with genotype data; OR=odds ratio; CI=confidence interval, UK=unknown.

Differences between total number of cases and controls and subjects shown in table are due to missing genotype information.

The genomic location of the SNP is determined using guidelines from the Human Genetic Variation Society ([den Dunnen and Antonarakis, 2001](#bib11){ref-type="other"}). If an rs number from the NCBI\'s dbSNP database is not available, the SNP is designated by an E number from the NCI\'s SNP500Cancer database (<http://snp500cancer.nci.nih.gov>).

###### 

Association between selected single nucleotide polymorphisms in *TERF2* and *TERT* and breast cancer risk among cases and controls, stratified by family history of breast cancer in first-degree female relatives

                                       **Homozygous common**   **Heterozygous**   **Homozygous variant**   **Per minor allele relative risk**                                            
  --------- -------------------- ----- ----------------------- ------------------ ------------------------ ------------------------------------ ----- ----- ------ ------ ------ ------- ------
  *TERF2*   IVS6+27G\>A          No    1496                    1243               592                      482                                  60    46    0.97   0.86   1.10   0.67     
            E3673_301            Yes   107                     146                20                       53                                   3     4     1.57   0.97   2.55   0.07    0.06
                                                                                                                                                                                          
  *TERT*    −1654A\>G            No    662                     598                1067                     857                                  415   324   0.92   0.85   1.01   0.09     
            rs2736109            Yes   40                      66                 65                       106                                  28    33    0.86   0.63   1.18   0.35    0.67
            −1381C\>T            No    661                     557                1093                     1001                                 469   412   1.02   0.94   1.11   0.63     
            rs2735940            Yes   34                      77                 74                       120                                  29    35    0.73   0.53   1.00   0.05    0.04
            −244C\>T             No    1159                    971                843                      694                                  148   116   0.97   0.88   1.07   0.56     
            rs2853669            Yes   65                      124                57                       72                                   10    8     0.66   0.46   0.95   0.03    0.05
            Ex2-659G\>A          No    1243                    1037               761                      634                                  130   93    0.96   0.86   1.07   0.44     
            A305A rs2736098      Yes   70                      134                50                       65                                   11    4     0.57   0.39   0.84   0.004   0.01
            IVS2-                No    1023                    810                898                      768                                  227   201   1.06   0.97   1.17   0.22     
            4601C\>T rs2736099   Yes   59                      105                59                       89                                   14    11    0.75   0.53   1.06   0.10    0.06

Differences between total number of cases and controls and subjects shown in table are due to missing genotype information.
